Kornimate/medical-research-clean huggingface dataset:
wine consumption and glycemic control

Conditions: Diabetes Mellitus, Type 2

Summary: many studies have reported that alcoholic beverage consumption, especially in the form of wine, reduces the risk of developing type 2 diabetes by as much as 40%. this association suggests that wine consumption may somehow improve the body's ability to control its blood glucose concentration. indeed, it has been reported that when wine is consumed immediately prior to ingestion of glucose, the release of insulin is enhanced and blood glucose concentration is lowered. the mechanism of wine's effects on blood glucose concentration is unknown, but is likely related to its ethanol or antioxidant content. in this study, the investigators plan to test whether wine or plain ethanol (vodka) ingestion alters the control of blood glucose in subjects who have diabetes or pre-diabetes.

our central hypothesis is that improvement in glycemic control by acute consumption of wine is mediated by ethanol. subjects will have type 2 diabetes, pre-diabetes, and be sedentary and obese (bmi \>30). subjects' glycemic control will be assessed by an oral glucose tolerance test (ogtt) at three different time points. one ogtt will occur shortly after consumption of red wine, the second after consumption of vodka containing the identical amount of ethanol as the wine treatment, and the third ogtt will occur shortly after consumption of an equal volume of water. the three ogtts will be administered in random order.

Eligibility criteria:
inclusion criteria: * insulin resistant: diagnosed with pre-diabetes or fasting blood glucose \>/= 97 mg/dl * t2d: diagnosed by primary care physician * at risk of type 2 diabetes (obesity and physically inactive) * age: 21-65 exclusion criteria: * smoking * insulin use (other than once daily) * physically active (\>30 mins aerobic exercise two days/week) * recent (\>3 mo) changes in medication use or dose * uncontrolled type two diabetes (hba1c \>10%) * advanced retinopathy or neuropathy * pregnancy

Keywords: type two diabetes glycemic control
effect of virtual reality on pain and function in children with sickle cell disease: a randomized controlled trial

Conditions: SCD

Summary: significance or rationale of the study: virtual reality (vr) is a promising non-pharmacological pain management tool. it enhances motor function by promoting cortical reorganization and neuroplasticity. its multimodal biofeedback engages sensory and cognitive functions, making therapy interactive, motivating, and easy to understand. with strong rehabilitation potential, vr helps patients adapt to real-world movements (laver, 2020). initially used for procedural pain management, vr is now expanding into chronic pain rehabilitation by encouraging engagement with difficult or avoided movements (griffin et al., 2020). additionally, vr offers a dynamic alternative to traditional exercises, improving adherence and outcomes. integrating entertainment into therapy can motivate children, enhancing their physical and psychological well-being. recently, a few studies revealed an improvement in vaso-occlusive episodes (voe) after vr treatment (agrawal et al., 2019). however, efficacy studies are needed to assess vr's potential benefits. additionally, data regarding vr's efficacy on daily pain, functional mobility, and hrqol as complementary therapy are limited

1. to investigate the effect of vr in reducing daily pain in children with scd 2. to evaluate the impact of vr on improving functional mobility in children with scd. 3. to examine the changes in pedsql in children with scd after engaging in vr experiences. 4. to evaluate the safety and satisfaction of fully immersive vr therapy in children with

Eligibility criteria:
inclusion criteria: 1. children aged between 8 and 13 years. 2. diagnosed with sickle cell disease (scd), including homozygous sca and other clinically confirmed variants. 3. medically stable and cleared by the treating physician to participate in mild activity. 4. receiving hydroxyurea as part of routine care. 5. able to follow simple instructions and communicate pain levels. 6. parental/legal guardian consent and child assent obtained. exclusion criteria: 1. presentence of developmental, neurological, or genetic disorders. 2. history of hip replacement or major orthopedic conditions affecting mobility. 3. current acute chest syndrome or unstable clinical condition. 4. visual or hearing impairments that would interfere with vr use. 5. participation in concurrent physiotherapy or rehabilitation programs. 6. previously enrolled in phase one of the current study (if applicable)

Keywords: sickle cell disease virtual reality numeric rating scale randomized controlled trial children health-related quality of life pain functional mobility
chinese antiphospholipid syndrome cohort collaborative networks

Conditions: Anti Phospholipid Syndrome

Summary: antiphospholipid syndrome (aps) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (apls). however, large-scale research on general population with persistent apls has been lacking. this project proposes to establish the first multicenter cohort of patients with persistently positive apls in china and conduct a comprehensive clinical phenotyping study. based on traditional phenotypes of thrombotic and pregnancy events, the focus will be on extra-standard clinical phenotypes and prospective assessment of event risk and prognosis in apl-positive population. a prospective analysis of extra-standard antibodies will also be conducted to recommend detection criteria for extra-standard antibody application in china and to assess their clinical significance.

chinese antiphospholipid syndrome cohort collaborative networks (capstone) is a national research network created to register patients with persistent apls. we aim at enrolling 2000 patients from a total of six centers, lead by the peking union medical college hospital (pumch). the apls assay will be validated in the central lab in pumch. all patients will be followed every six months, and up to three years. thrombotic and pregnancy events related to apls will be recorded, as well as extra-criteria clinical phenotypes.

Eligibility criteria:
inclusion criteria: * the presence of one or more of the antiphospholipid antibodies (apl) tested according to the 2006 sapporo aps clasification criteria, on two or more occasions at least 12 weeks apart: exclusion criteria: * patients refuse to participate; * unable to be followed.

Keywords: anti-phospholipid antibody
safety and efficacy of oxymetazoline hcl cream 1.0% in patients with persistent erythema associated with rosacea

Conditions: Erythema; Rosacea

Summary: this study will evaluate the safety and efficacy of oxymetazoline hydrochloride (hcl) cream 1.0% (agn-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.


Eligibility criteria:
inclusion criteria: -moderate to severe persistent facial erythema associated with rosacea. exclusion criteria: * greater than 3 inflammatory lesions on the face * current treatment with monoamine oxidase (mao) inhibitors * raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or sjogren's syndrome.
safety and superiority of penicillamine in radiosensitization of recurrent head and neck cancer

Conditions: Head and Neck Cancer; Recurrent Cancer

Summary: our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistance. therefore, the investigators plan to carry out a prospective interventional phase ii clinical trial to explore the safety and efficacy of penicillamine (a common copper chelator) as a radiosensitizer in the treatment of recurrent head and neck cancer.

head and neck cancer is the sixth most common cancer worldwide. radiotherapy is an important measure to control tumor recurrence. although radiotherapy has been widely used in patients with head and neck cancer, the 2-year local recurrence rate of patients with locally advanced disease is still as high as 50%-60%. this is associated with a lower radiosensitivity in head and neck cancer. high doses of reirradiation (\>60 gy) are associated with severe late complications and treatment-related mortality. therefore, finding an appropriate sensitizer to improve the radiosensitivity is the key to improve the survival of recurrent patients. our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and the results were published in j hepatol (if=25.7). penicillamine is a commonly used copper chelator in clinical practice and can reduce the concentration of copper in the body. based on this, the investigators plan to carry out a prospective interventional phase ii clinical trial to explore the safety and efficacy of penicillamine as a radiosensitizer in the treatment of recurrent head and neck cancer.

Eligibility criteria:
inclusion criteria: 1. sign informed consent 2. the age is 18-75 years 3. previously received standard radical radiotherapy or chemoradiotherapy 4. head and neck tumors with in situ or cervical lymph node recurrence confirmed by pathological biopsy and imaging examination 5. ecog ps：0/1 6. laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment. exclusion criteria: 1. after evaluation, it does not meet the indications of re-radiotherapy 2. unable to take oral medication 3. pregnancy or lactation 4. known allergy to penicillamine 5. patients who are judged by the researcher as unsuitable to participate in this trial.

Keywords: radiotherapy radiosensitizer penicillamine copper
traditional chinese medicine combined with thermal and cold ablation for early-stage lung cancer

Conditions: Non-small Cell Lung Cancer Stage I

Summary: lung cancer is the leading cause of cancer related mortality. at present, surgical treatment is the main choice for early-stage lung cancer. even after surgery, the 5-year recurrence rate is still as high as 18.4%-24%. traditional chinese medicine combined with thermal and cold ablation could be an alternative treatment. small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. the primary aim of this trial is to evaluate the efficacy of traditional chinese medicine combined with thermal and cold ablation for patients with stage i non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * the patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good. * patients with lung nodule. * maximum diameter of lung nodule ≥8mm. * the pathology of lung nodules biopsy was non-small cell lung cancer. * i period according to the eighth edition of the tnm staging period. * no mediastinal lymph node metastasis. * eastern cooperative oncology group performance status of 0 to 1. * no prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. * sufficient organ functions. exclusion criteria: * patients with previous use of various hormones, immunosuppression or autoimmune diseases. * women during pregnancy or breast-feeding. * patients with severe heart, lung, kidney disease or other systemic diseases * patients with severe hemorrhagic diseases. * patients with a history of drug abuse or mental illness. * other conditions that the investigator has determined are not suitable for participation in this study
delivering transcutaneous auricular neurostimulation to reduce blood loss during dialysis av graft placement procedures

Conditions: Blood Loss, Surgical

Summary: the objective of this study is to determine if tan therapy can reduce the volume of blood lost during dialysis av graft placement procedures.

this study is designed as a randomized, double-blind, sham-controlled, single-center, pilot clinical trial in which adults undergoing dialysis port placement procedures will be randomized 1:1 into one of two treatment groups: group 1: active tan + standard of care group 2: sham tan + standard of care participants will receive 30 minutes of active or sham tan immediately prior to the dialysis port placement procedure. blood loss and blood markers will be measured before and during the procedure to measure the effect of the therapy.

Eligibility criteria:
inclusion criteria: * participant is undergoing a dialysis port placement procedure using synthetic graft * participant is between 18 and 75 years of age * participant is english proficient * participant is able to provide informed consent and function at an intellectual level sufficient for study requirements exclusion criteria: * participant has a bmi ≥ 40 * participant is currently taking a platelet inhibitor medication * participant has a history of epileptic seizures * participant has a history of neurological diseases or traumatic brain injury * participant has presence of devices, e.g., pacemakers, cochlear prosthesis, neurostimulators * participant has abnormal ear anatomy or ear infection present * person of childbearing age, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study * person who is pregnant or lactating * participant has any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Keywords: auricular neurostimulation vagus nerve stimulation transcutaneous blood loss transcutaneous auricular neurostimulation tan
efficacy of the use of silver diamine fluoride and sodium fluoride varnish for the treatment of caries in children

Conditions: Dental Caries in Children

Summary: the goal of this observational study is to identify the efficacy of silver diamine fluoride 38% followed by sodium fluoride varnish 5% in a population with untreated dental caries age range 4 to 12 years old. the main questions to answer are * efficacy of treatment of active tooth decay with the treatment protocol of 38% silver diamine fluoride and 5% sodium fluoride varnish. * clinical evaluation of tooth decay treated with 38% silver diamine fluoride and 5% sodium fluoride varnish in quality of hardness, color change and caries progression. * explore the association of treatment with 38% silver diamine fluoride and 5% sodium fluoride varnish with: i. reduction of oral pain caused by the presence of carious lesions. ii. improvement in gingival oral health. iii. changes in general nutritional status through measurements of height, weight, hemoglobin levels and nutritional survey. the participants will be identified, charted (with nutritional surveys and parameters), as well as treated and compared in a six- and twelve-month period, where researchers will clinically identify the association between the use of this protocol and the efficacy of such, as well as other related nutritional aspects.


Eligibility criteria:
inclusion criteria: * the patient must be able to receive all necessary treatments and may be followed up for additional treatments and/or record follow-ups at each time point and for the duration of the study. * children within the age range mentioned above. * require a completed informed consent form and completed nutritional survey record for anyone who will participate in the program. * according to the evaluation of the dentist caries grade i and grade ii * in the case of patients with disabilities, at least one parent or legal guardian must be present at all times during the study. exclusion criteria: * patients who, after assessment, identify a pulp condition or abscess in any of the teeth, this affected piece will be excluded from receiving treatment with 38% silver diamine fluoride and 5% sodium fluoride varnish (in these cases, the patient coordinator will refer to a dentist outside the study for their treatment) * patients with caries with grade iii or grade iv * patients with a known allergy to any of the active ingredients ( 38% silver diamine fluoride and 5% sodium fluoride varnish) * patients who were unable to give their informed consent or complete the nutritional survey. * patients who cannot participate during the entire program (12 months). * patients with other oral treatments (orthodontics). * patients who are not present with at least one parent or legal guardian at the time of treatment.

Keywords: oral health dental caries silver diamine fluoride caries in children caviguard®
stress management for high blood pressure

Conditions: Prehypertension

Summary: the purpose of this research study is to examine the efficacy of two stress management interventions in reducing blood pressure (bp) in patients who have prehypertension (bp between 120/80 and 139/89). it is expected that participants will be better able to control their bp through reducing stress and increasing healthy lifestyle behaviors.


Eligibility criteria:
inclusion criteria: * unmedicated high blood pressure (sbp of 120-139 or dbp of 80-89) * bmi in the range of 19-40 * interest in attempting to control blood pressure through lifestyle modification exclusion criteria: * pacemakers * uncontrolled hypertension (sbp≥140 or dbp≥90) * atrial fibrillation * myocardial infarction (mi) * percutaneous transluminal coronary angioplasty (ptca) * coronary artery bypass graft (cabg) within 6 months of enrollment * congestive heart failure * uncorrected primary valvular disease hypertrophic or restrictive cardiomyopathy * uncorrected thyroid heart disease * chronic kidney disease * persistent tachyarrhythmia * jnc risk category c (target organ damage, diabetes) * patients who are pregnant or plan to become pregnant within 9 months * patients who are lactating * patients unable to comply with assessment procedures * patients with alcohol or drug abuse within 12 months * patients who consume more than 21 alcoholic drinks per week * patients who are current smokers * patients who are unable to provide informed consent or who have dementia * patients with previous extensive meditation or yoga training * patients with blood pressure ≥140/90

Keywords: randomized clinical trial early medical intervention intervention studies blood pressure stress management
a prospective/retrospective,randomized controlled clinical study of antiviral therapy in the 2019-ncov pneumonia

Conditions: 2019-nCoV

Summary: at present, there is no specific and effective antiviral therapy.in this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-ncov pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-ncov viral pneumonia, and to explore effective antiviral drugs for new coronavirus. to provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.


Eligibility criteria:
inclusion criteria: 1. 2019-ncov nucleic acid test was positive. 2. ct of the lung conformed to the manifestation of viral pneumonia. exclusion criteria: 1. patients who meet any of the contraindications in the experimental drug labeling 2. patients who do not want to participate in this clinical study
pharmacotherapy and intensive treatment of drug abuse - 1

Conditions: Cocaine-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.


Eligibility criteria:
please contact site for information.

Keywords: drug abuse
vinegar co-ingestion in type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.

plasma glucose and insulin concentrations are assessed over the 2 hr period following ingestion of carbohydrate-rich beverage with or without added vinegar.

Eligibility criteria:
inclusion criteria: * male type 2 diabetes * overweight or obese * 40-70 yrs exclusion criteria: * incident cardiovascular events during last year * peptic ulcer, duodenal ulcer, oesophageal reflux * antacids, h2 receptor blocker, proton pump inhibitors, nsaids, prokinetic agents
tamsulosin phase iii clinical trial -double-blind, placebo controlled study in male patients with lower urinary tract syndrome

Conditions: Urinary Tract Diseases

Summary: the purpose of this study is to determine whether tamusulosin is effective in the treatment of lower urinary tract syndrome with male patients.


Eligibility criteria:
inclusion criteria: * patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: luts). exclusion criteria: * patients with urination disorder accompanied by apparent organic(benign prostatic hyperplasia: bph) or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.

Keywords: tamsulosin urinary tract diseases male
efficacy of different anti-thrombotic strategies on device-related thrombosis prevention after percutaneous left atrial appendage occlusion

Conditions: Device-Related Thrombosis; Atrial Fibrillation; Left Atrial Appendage Occlusion

Summary: comparison among three different antithrombotic strategies after percutaneous laa occlusion with a watchman flx laac device.

data on the optimal antithrombotic therapy (at) after percutaneous left atrial appendage (laa) occlusion are still scarce. the classical at strategy after laa occlusion includes 6-weeks of warfarin + aspirin followed by dual anti platelet therapy with clopidogrel (75 mg) and aspirin (81-325 mg) until 6 months of follow-up, then aspirin alone is continued indefinitely. nonetheless, a significant number of patients continues to suffer from device-related thrombosis which carries a high risk of thromboembolic events. other at strategies have been tested in order to reduce the risk of thrombus-formation on device. among them, replacement of clopidogrel with half-dose oral anticoagulation (oac) in patients with genetic resistance to this drug has been recently reported to reduce the incidence of drt. additionally, reduced dose of novel oac was demonstrated to lead to lower thrombin generation compared to dapt.

Eligibility criteria:
inclusion criteria: * men and women ≥18 years of age * successful laac procedure (device implanted without procedural or bleeding complication). * patients contraindicated or unsuitable for long-term oac. * history of af (permanent or persistent or paroxysmal). * written informed consent by the patient or designee if the patient is unable to consent exclusion criteria: * life expectancy \< 2 years. * pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. * presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data

Keywords: left atrial appendage watchman antithrombotic therapy device-related thrombosis